biotech News - India

Biocon's clinical services arm Clingene is actively exploring an alliance with Mumbai-based clinical research organisation SIRO Clinpharm. http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Biocons-Clingene-SIRO-Clinpharm-in-alliance-talks/articleshow/5502878.cmshttp://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Biocons-Clingene-SIRO-Clinpharm-in-alliance-talks/articleshow/5502878.cmsTue, 26 Jan 2010 20:17:07 GMTBiocon's Clingene, SIRO Clinpharm in alliance talksBiocon's Clingene, SIRO Clinpharm in alliance talks

Biocon Limited today signed an MoU with Malaysia's Biotechnology Corporation (BiotechCorp) to explore collaboration and potential investment in Malaysia's biotechnology industry. http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Biocon-LTD-signs-MoU-with-Malaysian-based-BiotechCorp-/articleshow/5489564.cmshttp://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Biocon-LTD-signs-MoU-with-Malaysian-based-BiotechCorp-/articleshow/5489564.cmsFri, 22 Jan 2010 15:42:03 GMTBiocon LTD signs MoU with Malaysian-based BiotechCorp Biocon LTD signs MoU with Malaysian-based BiotechCorp

Reliance Life Sciences (RLS), a company promoted by Reliance Industries’ chairman, Mukesh Ambani, is looking at biopharmaceuticals as a huge thrust area. http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Reliance-Life-Sciences-bets-big-on-biosimilars/articleshow/5360256.cmshttp://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Reliance-Life-Sciences-bets-big-on-biosimilars/articleshow/5360256.cmsSun, 20 Dec 2009 20:30:37 GMTReliance Life Sciences bets big on biosimilarsReliance Life Sciences bets big on biosimilars

World’s second-largest generic drug maker Mylan, which held a majority stake in Ahmedabad-based Concord Biotech through its subsidiary Matrix Laboratories, has exited the biotech company by selling its stake to promoters.http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Mylan-sells-stake-in-Concord-Biotech/articleshow/5312185.cmshttp://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Mylan-sells-stake-in-Concord-Biotech/articleshow/5312185.cmsMon, 07 Dec 2009 18:38:17 GMTMylan sells stake in Concord BiotechMylan sells stake in Concord Biotech

US firm plans Rs 500 crore unit next to Tata Motors’ project.http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Nano-draws-biotech-giant-Alexandria-to-Gujarat/articleshow/5218206.cmshttp://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Nano-draws-biotech-giant-Alexandria-to-Gujarat/articleshow/5218206.cmsWed, 11 Nov 2009 04:56:05 GMTNano draws biotech giant Alexandria to GujaratNano draws biotech giant Alexandria to Gujarat

The US healthcare bill, which has been passed by the US House of Representatives and is awaiting nod from the Senate, holds a lot of promise for generic drug manufacturers from India. http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/US-health-bill-to-benefit-local-generic-firms/articleshow/5213728.cmshttp://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/US-health-bill-to-benefit-local-generic-firms/articleshow/5213728.cmsMon, 09 Nov 2009 19:34:09 GMTUS health bill to benefit local generic firmsUS health bill to benefit local generic firms

The Union Department of Science and Technology (DST) has embarked on several projects that are meant to go beyond social relevance. http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Lab-to-enterprise-solutions/articleshow/5193420.cmshttp://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Lab-to-enterprise-solutions/articleshow/5193420.cmsTue, 03 Nov 2009 15:09:27 GMTLab to enterprise solutionsLab to enterprise solutions

Pune-based research company Indus Biotech has received approval from the US Food and Drug Administration for clinical trails of its molecule, IND02, which can be used to treat AIDS and will begin the phase 1 trials in the US shortly, its MD Sunil Bhaskaran says.http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Indus-AIDS-molecule-gets-approval-for-clinical-trials/articleshow/5166064.cmshttp://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Indus-AIDS-molecule-gets-approval-for-clinical-trials/articleshow/5166064.cmsMon, 26 Oct 2009 18:30:41 GMTIndus’ AIDS molecule gets approval for clinical trialsIndus’ AIDS molecule gets approval for clinical trials

The Chennai-based Sanmar Group on Tuesday announced the sale of the closely held Bangalore Genei (India) (BGIP) to Merck Specialities.http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Merck-acquires-Sanmar-biz-in-Bangalore/articleshow/5120257.cmshttp://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Merck-acquires-Sanmar-biz-in-Bangalore/articleshow/5120257.cmsTue, 13 Oct 2009 11:20:40 GMTMerck acquires Sanmar biz in BangaloreMerck acquires Sanmar biz in Bangalore

Merck KGaA today announced the acquisition of Bangalore Genei (India) Private Limited by its wholly-owned subsidiary in India, Merck Specialities Pvt Ltd. http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Merck-KGaA-acquires-Bangalore-based-bioscience-company/articleshow/5119370.cmshttp://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Merck-KGaA-acquires-Bangalore-based-bioscience-company/articleshow/5119370.cmsTue, 13 Oct 2009 08:44:17 GMTMerck KGaA acquires Bangalore-based bioscience companyMerck KGaA acquires Bangalore-based bioscience company

Biocon Ltd, India's top listed biotechnology firm, said on Wednesday the firm would acquire the bulk pharmaceutical business undertaking of IDL Specialty Chemicals Ltd, located near Hyderabad. http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Biocon-to-buy-pharma-biz-of-IDL-Specialty/articleshow/5073216.cmshttp://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Biocon-to-buy-pharma-biz-of-IDL-Specialty/articleshow/5073216.cmsWed, 30 Sep 2009 15:19:28 GMTBiocon to buy pharma biz of IDL SpecialtyBiocon to buy pharma biz of IDL Specialty

Biotech major Biocon on Friday entered into a strategic tie-up with the US-based Amylin Pharmaceuticals to jointly produce a peptide hybrid molecule for treating diabetes. http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Biocon-US-firm-to-jointly-make-drug-for-diabetes/articleshow/5000222.cmshttp://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Biocon-US-firm-to-jointly-make-drug-for-diabetes/articleshow/5000222.cmsFri, 11 Sep 2009 14:44:09 GMTBiocon, US firm to jointly make drug for diabetesBiocon, US firm to jointly make drug for diabetes

The worrying development, according to WHO, has seen 12 countries, including China and Singapore, reporting a mutation in the virus. India has not reported the mutation so far. http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Drug-resistant-H1N1-reported-in-12-countries/articleshow/4953075.cmshttp://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Drug-resistant-H1N1-reported-in-12-countries/articleshow/4953075.cmsMon, 31 Aug 2009 01:30:05 GMTDrug-resistant H1N1 reported in 12 countriesDrug-resistant H1N1 reported in 12 countries

Biocon Ltd, India's top listed biotechnology firm, expects its branded formulations business in India to double this fiscal year as it launches new products, its chairman said.http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Biocon-sees-India-biz-growth-boost-from-Mylan-pact/articleshow/4935449.cmshttp://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/Biocon-sees-India-biz-growth-boost-from-Mylan-pact/articleshow/4935449.cmsWed, 26 Aug 2009 04:47:20 GMTBiocon sees India biz growth, boost from Mylan pactBiocon sees India biz growth, boost from Mylan pact

Buddhadeb Bhattacharjee, commerce & industry minister Nirupam Sen and finance minister Asim Dasgupta discussed the land-lease agreement of Nayachara island, where a mega chemical hub is proposed to come up.http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/APCRPL-plans-chemical-hub-at-Nayachara-island/articleshow/4916115.cmshttp://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/biotech/APCRPL-plans-chemical-hub-at-Nayachara-island/articleshow/4916115.cmsThu, 20 Aug 2009 15:34:20 GMTAPCRPL plans chemical hub at Nayachara islandAPCRPL plans chemical hub at Nayachara island

biotech News - World Wide

Background: Increased intracranial pressure (ICP) is a serious, life-threatening, secondary event following traumatic brain injury (TBI). In many cases, ICP rises in a delayed fashion, reaching a maximal level 48-96 hours after the initial insult. While pressure catheters can be implanted to monitor ICP, there is no clinically proven method for determining a patient's risk for developing this pathology. Methods: In the present study, we employed antibody array and Luminex-based screening methods to interrogate the levels of inflammatory cytokines in the serum of healthy volunteers and in severe TBI patients (GCS less than or equal to 8) with or without incidence of elevated intracranial pressure (ICP). De-identified samples and ELISAs were used to confirm the sensitivity and specificity of IL-6 as a prognostic marker of elevated ICP in both isolated TBI patients, and polytrauma patients with TBI. Results: Consistent with previous reports, we observed sustained increases in IL-6 levels in TBI patients irrespective of their ICP status. However, the group of patients who subsequently experienced ICP greater than or equal to 25mm Hg had significantly higher IL-6 levels within the first 17 hours of injury as compared to the patients whose ICP remained less than or equal to 20mm Hg. When blinded samples (n=22) were assessed, a serum IL-6 cut-off of <5pg/ml correctly identified 100% of all the healthy volunteers, a cut-off of >128pg/ml correctly identified 85% of isolated TBI patients who subsequently developed elevated ICP, and values between these cut-off values correctly identified 75% of all patients whose ICP remained less than or equal to 20mm Hg throughout the study period. In contrast, the marker had no prognostic value in predicting elevated ICP in polytrauma patients with TBI. When the levels of serum IL-6 were assessed in patients with orthopedic injury (n=7) in the absence of TBI, a significant increase was found in these patients compared to healthy volunteers, albeit lower than that observed in TBI patients. Conclusions: Our results suggest that serum IL-6 can be used for the differential diagnosis of elevated ICP in isolated TBI.

Objectives: To report the occurrence of a rare case of a huge benign ovarian tumour (mucinous cystadenoma) in Jazan city, Saudi Arabia.Patients: Our reported case was a middle-aged Saudi woman presented with marked abdominal distension and discomfort at the gynaecology clinic of Jazan General Hospital, Jazan city, Saudi Arabia. Methods: The data were collected by history-taking, clinical examination, laboratory investigations, transabdominal ultrasonographic examination, and by histo-pathological study of the excised surgical specimen. Results: The case was reported as a rare massive ovarian mucinous cystadenoma. Conclusions: This case report emphasizes the significance of thorough evaluation of all women presented with vague abdominal pains. Although the condition is extremely rare, it is a potentially dangerous in its massive form if not timely diagnosed and managed properly. With the increasing awareness of such conditions, more and more cases could be detected and reported early.

Background: Identification of novel drug targets and their inhibitors is a major challenge in the field of drug designing and development. Diaminopimelic acid (DAP) pathway is a unique lysine biosynthetic pathway present in bacteria, however absent in mammals. This pathway is vital for bacteria due to its critical role in cell wall biosynthesis. One of the essential enzymes of this pathway is dihydrodipicolinate synthase (DHDPS), considered to be crucial for the bacterial survival. In view of its importance, the development and prediction of potent inhibitors against DHDPS may be valuable to design effective drugs against bacteria, in general. Results: This paper describes a methodology for predicting novel/potent inhibitors against DHDPS. Here, quantitative structure activity relationship (QSAR) models were trained and tested on experimentally verified 23 enzyme's inhibitors having inhibitory value (Ki) in the range of 0.005-22(mM). These inhibitors were docked at the active site of DHDPS (1YXD) using AutoDock software, which resulted in 11 energy-based descriptors. For QSAR modeling, Multiple Linear Regression (MLR) model was engendered using best four energy-based descriptors yielding correlation values R/q2 of 0.82/0.67 and MAE of 2.43. Additionally, Support Vector Machine (SVM) based model was developed with three crucial descriptors selected using F-stepping remove-one approach, which enhanced the performance by attaining R/q2 values of 0.93/0.80 and MAE of 1.89. To validate the performance of QSAR models, external cross-validation procedure was adopted which accomplished high training/testing correlation values (q2/r2) in the range of 0.78-0.83/0.93-0.95. Conclusions: Our results suggests that ligand-receptor binding interactions for DHDPS employing QSAR modeling seems to be a promising approach for prediction of antibacterial agents. To serve the experimentalist to develop novel/potent inhibitors, a webserver "KiDoQ" has been developed (http://crdd.osdd.net/raghava/kidoq), which allows the prediction of Ki value of a new ligand molecule against DHDPS.

Background: Obesity has reached epidemic proportions in the United States. It is implicated in the development of a variety of chronic disease states and is associated with increased levels of inflammation and oxidative stress. The objective of this study is to examine the effect of Medifast's meal replacement program (MD) on body weight, body composition, and biomarkers of inflammation and oxidative stress among obese individuals following a period of weight loss and weight maintenance compared to a an isocaloric, food-based diet (FB). Methods: This 40-week randomized, controlled clinical trial included 90 obese adults with a body mass index (BMI) between 30 and 50 kg/m2, randomly assigned to one of two weight loss programs for 16 weeks and then followed for a 24-week period of weight maintenance. The dietary interventions consisted of Medifast's meal replacement program for weight loss and weight maintenance, or a self-selected, isocaloric, food-based meal plan. Results: Weight loss at 16 weeks was significantly better in the Medifast group (MD) versus the food-based group (FB) (12.3% vs. 6.9%), and while significantly more weight was regained during weight maintenance on MD versus FB, overall greater weight loss was achieved on MD versus FB. Significantly more of the MD participants lost [greater than or equal to]5% of their initial weight at week 16 (93% vs. 55%) and week 40 (62% vs. 30%). There was no difference in satiety observed between the two groups during the weight loss phase. Significant improvements in body composition were also observed in MD participants compared to FB at week 16 and week 40. At week 40, both groups experienced improvements in biochemical outcomes and other clinical indicators. Conclusions: Our data suggest that the meal replacement diet plan evaluated was an effective strategy for producing robust initial weight loss and for achieving improvements in a number of health-related parameters during weight maintenance, including inflammation and oxidative stress, two key factors more recently shown to underlie our most common chronic diseases.Trial Registration: ClinicalTrials.gov NCT01011491

Background: Surface contamination of smear cheese by Listeria spp. is of major concern for the industry. Complex smear ecosystems have been shown to harbor antilisterial potential but the microorganisms and mechanisms involved in the inhibition mostly remain unclear, and are likely related to complex interactions than to production of single antimicrobial compounds. Bacterial biodiversity and population dynamics of complex smear ecosystems exhibiting antilisterial properties in situ were investigated by Temporal temperature gradient gel electrophoresis (TTGE), a culture independent technique, for two microbial consortia isolated from commercial Raclette type cheeses inoculated with defined commercial ripening cultures (F) or produced with an old-young smearing process (M). Results: TTGE revealed nine bacterial species common to both F and M consortia, but consortium F exhibited a higher diversity than consortium M, with thirteen and ten species, respectively. Population dynamics were studied after application of the consortia on fresh-produced Raclette cheeses. TTGE analyses revealed a similar sequential development of the nine species common to both consortia. Beside common cheese surface bacteria (Staphylococcus equorum, Corynebacterium spp., Brevibacterium linens, Microbacterium gubbeenense, Agrococcus casei), the two consortia contained marine lactic acid bacteria (Alkalibacterium kapii, Marinilactibacillus psychrotolerans) that developed early in ripening (day 14 to 20), shortly after the growth of staphylococci (day 7). A decrease of Listeria counts was observed on cheese surface inoculated at day 7 with 0.1-1 x 10(2) CFU cm(-2), when cheeses were smeared with consortium F or M. Listeria counts went below the detection limit of the method between day 14 and 28 and no subsequent regrowth was detected over 60 to 80 ripening days. In contrast, Listeria grew to high counts (10(5) CFU cm(-2)) on cheeses smeared with a defined surface culture. Conclusions: This work reports the first population dynamics study of complex smear ecosystems exhibiting in situ antilisterial activity. TTGE revealed the presence of marine lactic acid bacteria that are likely related to the strong Listeria inhibition, as their early development in the smear occurred simultaneously with a decrease in Listeria cell count.

Background: Adult T cell leukemia results from the malignant transformation of a CD4+ lymphoid clone carrying an integrated HTLV-1 provirus that has undergone several oncogenic events over a 30-60 year period of persistent clonal expansion. Both CD4+ and CD8+ lymphocytes are infected in vivo; their expansion relies on CD4+ cell cycling and on the prevention of CD8+ cell death. Cloned infected CD4+ but not CD8+ T cells from patients without malignancy also add up nuclear and mitotic defects typical of genetic instability related to the expression of the virus-encoded oncogene tax. HTLV-1 expression is cancer-prone in vitro, but in vivo numerous selection forces act to maintain T cell homeostasis and are possibly involved in clonal selection. Results: Here we demonstrate that the HTLV-1 associated CD4+ preleukemic phenotype and the specific patterns of CD4+ and CD8+ clonal expansion are in vivo selected processes. By comparing the effects of recent (1 month) experimental infections performed in vitro and those observed in cloned T cells from patients infected for > 6-26 years, we found that in chronically HTLV-1 infected individuals, HTLV-1 positive clones are selected for tax expression. In vivo, infected CD4+ cells are positively selected for cell cycling whereas infected CD8+ cells and uninfected CD4+ cells are negatively selected for the same processes. In contrast, the known HTLV-1-dependent prevention of CD8+ T cell death pertains to both in vivo and in vitro infected cells. Conclusions: Therefore, virus-cell interactions alone are not sufficient to initiate early leukemogenesis in vivo.

Background: The number of hip fractures during recent decades has been reported to be increasing, partly because of an increasing proportion of elderly women in the society. However, whether changes in hip fracture annual incidence in women are attributable to secular changes in the prevalence of osteoporosis is unclear. Methods: Bone mineral density was evaluated by single-photon absorptiometry at the distal radius in 456 women aged 50 years or above and living in the same city. The measurements were obtained by the same densitometer during three separate time periods: 1970-74 (n=106), 1987-93 (n=175) and 1998-1999 (n=178), and the age-adjusted prevalence of osteoporosis in these three cohorts was calculated. Additionally, all hip fractures sustained in the target population of women aged 50 years or above between 1967 and 2001 were registered, whereupon the crude and the age-adjusted annual incidence of hip fractures were calculated. Results: There was no significant difference in the age-adjusted prevalence of osteoporosis when the three cohorts were compared (P=1.00). The crude annual incidence (per 10,000 women) of hip fracture in the target population increased by 110% from 40 in 1967 to 84 in 2001. The overall trend in the crude incidence between 1967 and 2001 was increasing (1.58 per 10,000 women per year; 95 percent confidence interval, 1.17 to 1.99), whereas the age-adjusted incidence was stable over the same period (0.22 per 10,000 women per year; 95 percent confidence interval, -0.16 to 0.60). Conclusions: The increased number of hip fracture in elderly women is more likely to be attributable to demographic changes in the population than to secular increase in the prevalence of osteoporosis.

Background: Despite recommendations for outpatient management, low risk patients with lower respiratory tract infections (LRTIs) are often hospitalized. This survey analyzed perceptions of physicians, nurses, patients and relatives about feasibility of outpatient management and required duration of hospital stay. Methods: We performed a prospective, observational questionnaire survey in hospitalized patients with LRTI as part of a multicenter trial. Treating physicians and nurses, patients and their relatives were asked on admission and before discharge about feasibility of outpatient treatment over 5 dimensions (medical, nursing, organizational factors, and patients' and relatives' preferences) using continuous scales. Results: On admission, 12.6% of physicians, 15.1% of nurses, 18.0% of patients and 5.2% of relatives believed that outpatient treatment would be possible. Before hospital discharge, 31.1% of physicians, 32.2% of nurses, 11.6% of patients and 4.1% of relatives thought that earlier discharge would have been feasible. Medical factors were the most frequently perceived motives for inpatient management. These perceptions were similar in all LRTI subgroups and independent of disease severity and associated expected mortality risks as assessed by the Pneumonia Severity Index (PSI). Conclusion: Independent of type and severity of respiratory tract infection, the misperceived high severity and expected mortality and morbidity were the predominant reasons why treating physicians, nurses, patients and their relatives unanimously believed that inpatient management was necessary. Better assessment and communication about true expected medical risks might contribute to a pathway to shorten in-hospital days and to introduce a more risk-targeted and individually tailored allocation of health-care resources.Trial Registration: NCT00350987

Background: Remodeling of the extracellular matrix (ECM) has been implicated in ovarian cancer, and we hypothesize that these alterations may provide a better optical marker of early disease than currently available imaging/screening methods and that understanding their physical manifestations will provide insight into invasion. Methods: For this investigation we use Second Harmonic Generation (SHG) imaging microcopy to study changes in the structure of the ovarian ECM in human normal and malignant ex vivo biopsies. This method directly visualizes the type I collagen in the ECM and provides quantitative metrics of the fibrillar assembly. To quantify these changes in collagen morphology we utilized an integrated approach combining 3D SHG imaging measurements and bulk optical parameter measurements in conjunction with Monte Carlo simulations of the experimental data to extract tissue structural properties. Results: We find the SHG emission attributes (directionality and relative intensity) and bulk optical parameters, both of which are related to the tissue structure, are significantly different in the tumors in a manner that is consistent with the change in collagen assembly. The normal and malignant tissues have highly different collagen fiber assemblies, where collectively, our findings show that the malignant ovaries are characterized by lower cell density, denser collagen, as well as higher regularity at both the fibril and fiber levels. This further suggests that the assembly in cancer may be comprised of newly synthesized collagen as opposed to modification of existing collagen. Conclusions: Due to the large structural changes in tissue assembly and the SHG sensitivity to these collagen alterations, quantitative discrimination is achieved using small patient data sets. Ultimately these measurements may be developed as intrinsic biomarkers for use in clinical applications.

Background: To investigate prospectively the patient-relevant outcome 7 years after total hip replacement (THR) for osteoarthritis (OA).Method219 consecutive patients (120 women) with primary OA, mean age 71 (range 50-92) were assigned for THR. They were examined preoperatively, at 3, 6, 12 months, and at 4, 5 and 7 years postoperatively with the self-administered questionnaires SF-36 and WOMAC. Supplementary questions regarding postoperative complications, general co-morbidity, social circumstances and patient satisfaction were asked at the three last follow-ups. A reference group, 117 subjects (67 women), mean age 72 (range 52-92) without hip complaints were recruited from the community and investigated at the same times. Results: 151/170 (89%) of the patients and 65/74 (88%) of the reference group participated at the 7 year follow-up. The best postoperative result was reported one year postoperatively. At the 7 year follow up there was a significant difference between the patients and controls in SF-36 physical function (PF) and role physical (RP) but not of WOMAC function. There was no difference in frequency of co-morbid conditions between those operated and the reference group, but those operated were in greater need of walking aid (46% vs. 8% p<0.0001) and reported more regional and widespread pain (68% vs. 53% p<0.05). Conclusion: This study shows that in an unselected cohort the patients experience a similar health-related quality of life as a reference group of a similar age and sex structure 7 years after THR except for general physical function where the patients score worse.

bioperform News